Interpharma Investments Limited appoints Shai Ganu as Member of Board of Directors

Interpharma Investments Limited (IIL), holding company of leading healthcare solutions company Zuellig Pharma, is pleased to announce the appointment of Mr. Shai Ganu as a new member of the IIL Board of Directors effective 1 November 2023.

Mr. Ganu is an independent director and ESG, remuneration and nominations committee expert. He has extensive experience in working closely with Boards and management teams of some of the world’s largest companies on issues related to board and executive pay, performance and incentives, ESG and climate transition, board effectiveness, and work culture transformation.

He also serves as an Independent Director (INED) on several SGX-listed companies such as Far East Orchard and TeleChoice International as well as SATA CommHealth, a private healthcare and community care organisation. He is a global board member of the World Economic Forum’s (WEF) climate governance initiative and a governing council member of the Singapore Institute of Directors (SID).

The IIL Board would like to take this opportunity to welcome Mr Ganu, as he leads Zuellig Pharma to greater heights.